#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Uveal melanoma Meningitis meningococcal Carcinoid syndrome Juvenile chronic myelomonocytic leukaemia Netherton's syndrome Extra-osseous Ewing's sarcoma metastatic Wiskott-Aldrich syndrome Cholestatic pruritus Arterial tortuosity syndrome Neoplasm malignant Infantile spasms Emphysema Neurodevelopmental disorder Acquired haemophilia More trials…

    Learn about Rare Diseases

    Myxofibrosarcoma – Trials in Disease Cystic fibrosis lung – Life with Disease Hereditary angioedema Noonan syndrome – Treatment Loeys-Dietz syndrome – Basic Information Marginal zone lymphoma refractory Behcet’s syndrome – Diagnostics Brain stem glioma – Treatment Choroid melanoma – Treatment CADASIL – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Salbutamol Sulfate Teprenone MAPLIRPACEPT Rhh646 Human Fibrinogen HYALURONIDASE 4-IODOPHENYLALANINE I-131 Poa Pratensis Vusolimogene Oderparepvec Air, Medicinal Quizartinib Dihydrochloride Emtricitabine ALPROSTADIL ASP3082 [18F]-Altanserin Yttrium-90 Belinostat Adrenaline Acid Tartrate Bp 177LU-FAP-2286 CARBOMER 980 More therapies…

    Learn about Your Condition

    Spinal muscular atrophy Ovarian cancer recurrent Cryoglobulinaemia Substance use disorder Pancreatic carcinoma stage IV Lung adenocarcinoma stage III Vascular graft thrombosis Metastasis Monkeypox Deafness Muscle strain Underweight Thalassaemia beta Micrographic skin surgery Thrombotic microangiopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Study on the Safety and Effects of GEN1055 Alone and with Pembrolizumab for Patients with Malignant Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Gen1055
    • Pemetrexed Disodium
    • Carboplatin
    Spain

  • Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Linrodostat Mesilate
    • Relatlimab
    • Ipilimumab
    France Italy Spain

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • 3-[6-(1-Benzylpiperidin-4-Yl)-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Canakinumab
    • Capmatinib
    Belgium Czechia France Germany Hungary Italy +2

  • Study of AFM24 and Atezolizumab for Patients with Advanced or Metastatic EGFR-expressing Cancers

    Not recruiting

    1 1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Afm24
    • Ramucirumab
    • Atezolizumab
    Poland Spain

  • Study of BT5528 alone and with nivolumab in patients with advanced solid tumors that have EphA2 protein expression

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Monomethyl Auristatin E Linked To A Sarcosine Decamer With A Beta-Alanine N-Terminus And Bcy9594 Via A Cleavable Linker
    • Nivolumab
    Belgium Spain

  • Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Czechia France Germany Hungary Spain
Previous Page
1 … 13 14 15 16 17 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!